News
Merck gets another quick return on its $3.9bn SpringWorks takeover with EU approval of Ezmekly for tumours caused by neurofibromatosis type 1.
See the latest Merck & Co Inc stock price (MRK:XNYS), related news, valuation, dividends and more to help you make your investing decisions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback